Given the need for expanded diagnostic testing, many point-of-care tests for COVID-19 have been rapidly developed for both medical
and public use. However, the pace of assay development has at times exceeded rigorous evaluation, and uncertainties remain about the
accuracy and reliability of these kits. Andy Lane at The Native Antigen Company showcases the need for rapid point-of-care (PoC) testing, issues surrounding reliability and validation, and how the choice of reagents can affect diagnostic performance.